-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
ATyr Pharma Announces Dosing Of First Patient In Pivotal Phase 3 EFZO-FIT Study Of Efzofitimod In Patients With Pulmonary Sarcoidosis
ATyr Pharma Announces Dosing Of First Patient In Pivotal Phase 3 EFZO-FIT Study Of Efzofitimod In Patients With Pulmonary Sarcoidosis
Multiple centers in the U.S. are open for enrollment for double-blind, randomized, placebo-controlled study.
Primary endpoint will evaluate steroid-sparing effect of efzofitimod compared to placebo.
EFZO-FIT builds on positive results from Phase 1b/2a study which demonstrated dose dependent improvements across steroid reduction, lung function and symptom control endpoints.
SAN DIEGO, Sept. 27, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that it has dosed the first patient in the global pivotal EFZO-FIT study. The Phase 3 study will evaluate the efficacy and safety of the company's lead therapeutic candidate, efzofitimod, compared to placebo in patients with pulmonary sarcoidosis, a major form of interstitial lung disease (ILD).
Efzofitimod is a first-in-class immunomodulator that downregulates innate and adaptive immune responses in uncontrolled inflammatory diseases states via selective modulation of neuropilin-2 (NRP2). The design of the EFZO-FIT study is supported by safety and efficacy data from a Phase 1b/2a study of efzofitimod in patients with pulmonary sarcoidosis. Efzofitimod has been granted FDA Orphan Drug and Fast Track designations for sarcoidosis.
"We are delighted to begin patient dosing in EFZO-FIT. With multiple centers in the U.S. open for enrollment, this very important study for patients with pulmonary sarcoidosis is underway," said Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer of aTyr. "This is an important step forward to delivering a transformative, disease modifying therapy that we believe can reduce the burden of steroids and provide clinically meaningful outcomes for patients with this complex disease."
"We are excited to collaborate with aTyr as they advance this study of a promising new treatment that could potentially improve the lives of sarcoidosis patients worldwide," said Mary McGowan, Chief Executive Officer of the Foundation for Sarcoidosis Research.
The EFZO-FIT study is a global Phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of efzofitimod in patients with pulmonary sarcoidosis. This is a 52-week study consisting of three parallel cohorts randomized equally to either 3.0 mg/kg or 5.0 mg/kg of efzofitimod or placebo dosed intravenously once a month for a total of 12 doses. The study intends to enroll 264 subjects with pulmonary sarcoidosis at multiple centers in North America, Europe and Japan. The trial design will incorporate a forced steroid taper. The primary endpoint of the study is steroid reduction. Secondary endpoints include measures of lung function and sarcoidosis symptoms.
More information on the EFZO-FIT study is available at (NCT05415137) and .
Multiple centers in the U.S. are open for enrollment for double-blind, randomized, placebo-controlled study.
美国的多个中心开放参加双盲、随机、安慰剂对照研究。
Primary endpoint will evaluate steroid-sparing effect of efzofitimod compared to placebo.
主要终点将评估efzofitimod与安慰剂相比的类固醇节省效果。
EFZO-FIT builds on positive results from Phase 1b/2a study which demonstrated dose dependent improvements across steroid reduction, lung function and symptom control endpoints.
EFZO-FIT建立在1b/2a期研究的积极结果基础上,该研究表明,类固醇减少、肺功能和症状控制终点的改善依赖于剂量。
SAN DIEGO, Sept. 27, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that it has dosed the first patient in the global pivotal EFZO-FIT study. The Phase 3 study will evaluate the efficacy and safety of the company's lead therapeutic candidate, efzofitimod, compared to placebo in patients with pulmonary sarcoidosis, a major form of interstitial lung disease (ILD).
圣迭戈,9月2022年3月27日(环球网)--生物治疗公司泰尔制药公司(纳斯达克市场代码:LIFE)今天宣布,它已经为全球关键的EFZO-FIT研究中的首位患者开出了药物剂量。第三阶段研究将评估该公司的主要候选治疗药物efzofitimod与安慰剂治疗肺结节病患者的疗效和安全性。肺结节病是间质性肺部疾病(ILD)的一种主要形式。
Efzofitimod is a first-in-class immunomodulator that downregulates innate and adaptive immune responses in uncontrolled inflammatory diseases states via selective modulation of neuropilin-2 (NRP2). The design of the EFZO-FIT study is supported by safety and efficacy data from a Phase 1b/2a study of efzofitimod in patients with pulmonary sarcoidosis. Efzofitimod has been granted FDA Orphan Drug and Fast Track designations for sarcoidosis.
Efzofitimod是一种一流的免疫调节剂,通过选择性调节神经粘连蛋白-2(NRP2),在无法控制的炎症性疾病状态下下调固有和获得性免疫反应。EFZO-FIT试验的设计得到了EFZO-FIT试验1b/2a期试验的安全性和有效性数据的支持,该试验用于肺结节病患者。Efzofitimod已被FDA授予治疗结节病的孤儿药物和快速通道称号。
"We are delighted to begin patient dosing in EFZO-FIT. With multiple centers in the U.S. open for enrollment, this very important study for patients with pulmonary sarcoidosis is underway," said Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer of aTyr. "This is an important step forward to delivering a transformative, disease modifying therapy that we believe can reduce the burden of steroids and provide clinically meaningful outcomes for patients with this complex disease."
ATyr首席执行官桑杰·S·舒克拉医学博士兼首席执行官桑杰·S·舒克拉说:“我们很高兴开始给患者服用EFZO-FIT。随着美国的多个中心开放招生,这项针对肺结节病患者的非常重要的研究正在进行中。这是朝着提供一种变革性的疾病修正疗法迈出的重要一步,我们相信这种疗法可以减轻类固醇的负担,并为这种复杂疾病的患者提供临床上有意义的结果。“
"We are excited to collaborate with aTyr as they advance this study of a promising new treatment that could potentially improve the lives of sarcoidosis patients worldwide," said Mary McGowan, Chief Executive Officer of the Foundation for Sarcoidosis Research.
结节病研究基金会首席执行官玛丽·麦高恩说:“我们很高兴能与aTyr公司合作,因为他们正在推进这项有前景的新疗法的研究,这种疗法可能会改善世界各地结节病患者的生活。
The EFZO-FIT study is a global Phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of efzofitimod in patients with pulmonary sarcoidosis. This is a 52-week study consisting of three parallel cohorts randomized equally to either 3.0 mg/kg or 5.0 mg/kg of efzofitimod or placebo dosed intravenously once a month for a total of 12 doses. The study intends to enroll 264 subjects with pulmonary sarcoidosis at multiple centers in North America, Europe and Japan. The trial design will incorporate a forced steroid taper. The primary endpoint of the study is steroid reduction. Secondary endpoints include measures of lung function and sarcoidosis symptoms.
EFZO-FIT这项研究是一项全球性的3期随机、双盲、安慰剂对照研究,旨在评估efzofitimod在肺结节病患者中的疗效和安全性。这是一项为期52周的研究,包括三个平行的队列,随机分为3.0 mg/kg或5.0 mg/kg的efzofitimod或安慰剂,每月静脉注射一次,共12剂。这项研究打算在北美、欧洲和日本的多个中心招募264名肺结节病患者。试验设计将纳入强制类固醇缩减。这项研究的主要终点是类固醇减少。次要终点包括肺功能和结节病症状的测量。
More information on the EFZO-FIT study is available at (NCT05415137) and .
有关EFZO-FIT的更多信息研究报告可在(NCT05415137)和。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧